4 Reasons why the pharma industry is facing exponential change

The global pharmaceutical industry is experiencing exponential change. A mass of conflicting drivers are competing to make the prediction of value ever more complex. 1) Demographics – Demographics are pushing market potential upwards through an ageing population and the move to lifestyle related diseases in the increasingly affluent developing markets of the world. 2) Economic climate – The counter pressures …

What does the new European pharmacovigilance legislation mean for pharma?

Pharma is still on the cusp of the EU pharmacovigilance legislation changes that are part of the drive to improve patient safety in Europe. I wanted to discuss the next milestones in the EMAs European legislation changes and what pharma should be looking at. The EMA amendments to the way drug safety is monitored and reported in Europe are well …

Video: Sylvie Grégoire of Shire on corporate social responsibility and #RareDiseases

Dr. Sylvie Grégoire, President of Shire Human Genetic Therapies, presented at last year's World Orphan Drug Congress USA on the topic ‘The social responsibility of companies working with orphan diseases.' Do you want to learn more about: Differentiating the orphan drug market from the traditional pharma market Focusing on patients and personalized marketing: a paradigm shift to market drugs in …

Top themes for 2012 – EU legislation, signal analysis and benefit risk

Top drug safety themes for 2012 – EU legislation, signal analysis and benefit/risk. The World Drug Safety Congress Europe 2012 has a brand new producer working on it, our in- office action man, Nick. He is bringing some fresh eyes to the event and has spent the last few weeks researching the topic inside and out. He has been speaking …

New European pharmacovigilance legislation – what are pharma saying about it?

The new European pharmacovigilance legislation for human use – how is the industry responding to the changes and what are they expecting the impact will be on safety strategy and practical implications. We've been listening to the industry on this and its been great hearing what pharma has to shout about including their expectations, the good, the bad and the …